Investor Relations

Financial calendar


 

Subscribe to calendar

Latest press releases

ExpreS2ion files clinical trial amendment to enable combination testing of ES2B-C001 with antibody-drug conjugates and to expand the number of study sites

Hørsholm, Denmark, 13 May 2025 - ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”), a clinical-stage biotechnology company developing vaccine candidates for infectious diseases and cancer, today announced that it has submitted a study protocol amendment to the Austrian regulatory authorities to enable the evaluation of its breast cancer vaccine candidate, ES2B-C001, in combination with…

Read more

ExpreS2ion to Present in Upcoming Investor Events

Hørsholm, Denmark, 9 May 2025 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce its participation in two key upcoming investor events: Bio€quity Europe and a webinar presentation of interim results for Q1 2025.

Read more

ExpreS2ion annual report for 2024 published

Hørsholm, Denmark, 1 May 2025 - ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that the Annual Report for the financial year 2024 has been published. The Annual Report is available as an attachment to this press release and can be accessed on the Company’s website at: https://investor.expres2ionbio.com/reports/

Read more

Latest presentations

2024 Q4 and Full-Year
Report Webcast

6 February 2025

Stora Aktiedagarna
Stockholm

27 November 2024

Biostock
Life Science Summit

21 November 2024